echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Harmonicare Pharmaceuticals completes the first interim analysis of the Phase III clinical trial of Tenacept

    Harmonicare Pharmaceuticals completes the first interim analysis of the Phase III clinical trial of Tenacept

    • Last Update: 2022-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 12, Harbin Pharmaceutical announced that the Phase III registration clinical trial of its new drug ternacept (HBM9036) in China has completed the first interim analysis


    Tenacept (HBM9036) is a globally innovative tumor necrosis factor (TNF) receptor-1 fragmented drug for adults with moderate to severe dry eye (DED)


    The trial is planned to enroll 674 subjects and conduct two interim analyses over the course of the trial


    As of the announcement date, participants in the trial remained blinded to drug or placebo administration


    Dry eye is a chronic ocular surface disease caused by a variety of factors, which can cause visual impairment and long-term damage to the ocular surface, seriously affecting the quality of life


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.